» Articles » PMID: 38423750

Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders

Overview
Journal Mol Pharmacol
Date 2024 Feb 29
PMID 38423750
Authors
Affiliations
Soon will be listed here.
Abstract

Metabotropic glutamate receptor 7 (mGlu) is the most highly conserved and abundantly expressed mGlu receptor in the human brain. The presynaptic localization of mGlu, coupled with its low affinity for its endogenous agonist, glutamate, are features that contribute to the receptor's role in modulating neuronal excitation and inhibition patterns, including long-term potentiation, in various brain regions. These characteristics suggest that mGlu modulation may serve as a novel therapeutic strategy in disorders of cognitive dysfunction, including neurodevelopmental disorders that cause impairments in learning, memory, and attention. Primary mutations in the gene have recently been identified as novel causes of neurodevelopmental disorders, and these patients exhibit profound intellectual and cognitive disability. Pharmacological tools, such as agonists, antagonists, and allosteric modulators, have been the mainstay for targeting mGlu in its endogenous homodimeric form to probe effects of its function and modulation in disease models. However, recent research has identified diversity in dimerization, as well as trans-synaptic interacting proteins, that also play a role in mGlu signaling and pharmacological properties. These novel findings represent exciting opportunities in the field of mGlu receptor drug discovery and highlight the importance of further understanding the functions of mGlu in complex neurologic conditions at both the molecular and physiologic levels. SIGNIFICANCE STATEMENT: Proper expression and function of mGlu is essential for learning, attention, and memory formation at the molecular level within neural circuits. The pharmacological targeting of mGlu is undergoing a paradigm shift by incorporating an understanding of receptor interaction with other and acting synaptic proteins, as well as various intracellular signaling pathways. Based upon these new findings, mGlu's potential as a drug target in the treatment of cognitive disorders and learning impairments is primed for exploration.

Citing Articles

The Role of Photobiomodulation to Modulate Ion Channels in the Nervous System: A Systematic Review.

Zhang Z, Zhang Z, Liu P, Xue X, Zhang C, Peng L Cell Mol Neurobiol. 2024; 44(1):79.

PMID: 39579175 PMC: 11585518. DOI: 10.1007/s10571-024-01513-1.

References
1.
Thibado J, Tano J, Lee J, Salas-Estrada L, Provasi D, Strauss A . Differences in interactions between transmembrane domains tune the activation of metabotropic glutamate receptors. Elife. 2021; 10. PMC: 8102066. DOI: 10.7554/eLife.67027. View

2.
Bushell T, Sansig G, Collett V, van der Putten H, Collingridge G . Altered short-term synaptic plasticity in mice lacking the metabotropic glutamate receptor mGlu7. ScientificWorldJournal. 2003; 2:730-7. PMC: 6009301. DOI: 10.1100/tsw.2002.146. View

3.
Palazzo E, Romano R, Luongo L, Boccella S, De Gregorio D, Giordano M . MMPIP, an mGluR7-selective negative allosteric modulator, alleviates pain and normalizes affective and cognitive behavior in neuropathic mice. Pain. 2015; 156(6):1060-1073. DOI: 10.1097/j.pain.0000000000000150. View

4.
Linden A, Greene S, Bergeron M, Schoepp D . Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology. 2003; 29(3):502-13. DOI: 10.1038/sj.npp.1300321. View

5.
Park S, Kim B, Cho S, Kim J, Kim J, Shin M . The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014; 24(4):223-7. DOI: 10.1089/cap.2013.0079. View